
<document id="DBMI.pac72" origId="pac72">
	<sentence id="DBMI.pac72.s0" origId="s0" text="7 DRUG INTERACTIONS\n\n7.1 CNS Depressants\nOther central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma."/>
	<sentence id="DBMI.pac72.s1" origId="s1" text="Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents."/>
	<sentence id="DBMI.pac72.s2" origId="s2" text="7.2 Muscle Relaxants\nOxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression."/>
	<sentence id="DBMI.pac72.s3" origId="s3" text="7.3 Mixed Agonist/Antagonist Opioid Analgesics\nDo not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride."/>
	<sentence id="DBMI.pac72.s4" origId="s4" text="In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms."/>
	<sentence id="DBMI.pac72.s5" origId="s5" text="7.4 Agents Affecting Cytochrome P450 Enzymes\n\nCYP3A4 Inhibitors\nA published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.">
		<entity charOffset="1123-1136" id="DBMI.pac72.s5.e0" origId="s5.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="1210-1220" id="DBMI.pac72.s5.e1" origId="s5.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac72.s5.e0" e2="DBMI.pac72.s5.e1" id="DBMI.pac72.s5.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="oxycodone " precipitant="voriconazole "/>
		<pair e1="DBMI.pac72.s5.e1" e2="DBMI.pac72.s5.e0" id="DBMI.pac72.s5.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac72.s6" origId="s6" text="Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects."/>
	<sentence id="DBMI.pac72.s7" origId="s7" text="If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibitors."/>
	<sentence id="DBMI.pac72.s8" origId="s8" text="Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved."/>
	<sentence id="DBMI.pac72.s9" origId="s9" text="[see Clinical Pharmacology (12.3)]\n\nCYP3A4 Inducers\nA published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations.">
		<entity charOffset="1800-1809" id="DBMI.pac72.s9.e0" origId="s9.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="1877-1887" id="DBMI.pac72.s9.e1" origId="s9.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac72.s9.e0" e2="DBMI.pac72.s9.e1" id="DBMI.pac72.s9.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="oxycodone " precipitant="rifampin "/>
		<pair e1="DBMI.pac72.s9.e1" e2="DBMI.pac72.s9.e0" id="DBMI.pac72.s9.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentence>
	<sentence id="DBMI.pac72.s10" origId="s10" text="Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone."/>
	<sentence id="DBMI.pac72.s11" origId="s11" text="If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inducers."/>
	<sentence id="DBMI.pac72.s12" origId="s12" text="Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved."/>
	<sentence id="DBMI.pac72.s13" origId="s13" text="[see Clinical Pharmacology (12.3)]\n\nCYP2D6 Inhibitors\nOxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6."/>
	<sentence id="DBMI.pac72.s14" origId="s14" text="While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent."/>
	<sentence id="DBMI.pac72.s15" origId="s15" text="However, clinicians should be aware of this possible interaction."/>
	<sentence id="DBMI.pac72.s16" origId="s16" text="7.5 Monoamine Oxidase Inhibitors (MAOIs)\n\nNo specific interaction between oxycodone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate."/>
	<sentence id="DBMI.pac72.s17" origId="s17" text="7.6 Anticholinergics\n\nAnticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus."/>
	<sentencespan id="DBMI.pac72.sp0" origId="sp0" text="7 DRUG INTERACTIONS\n\n7.1 CNS Depressants\nOther central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma. Use oxycodone hydrochloride with caution and in reduced dosages in patients taking these agents. 7.2 Muscle Relaxants\nOxycodone hydrochloride may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression."/>
	<sentencespan id="DBMI.pac72.sp1" origId="sp1" text="7.3 Mixed Agonist/Antagonist Opioid Analgesics\nDo not administer mixed agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride. In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms. 7.4 Agents Affecting Cytochrome P450 Enzymes\n\nCYP3A4 Inhibitors\nA published study showed that the co-administration with voriconazole, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone.">
		<entity charOffset="1123-1136" id="DBMI.pac72.sp1.e0" origId="sp1.e0" text="voriconazole " type="Active ingredient"/>
		<entity charOffset="1210-1220" id="DBMI.pac72.sp1.e1" origId="sp1.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac72.sp1.e0" e2="DBMI.pac72.sp1.e1" id="DBMI.pac72.sp1.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="oxycodone " precipitant="voriconazole "/>
		<pair e1="DBMI.pac72.sp1.e1" e2="DBMI.pac72.sp1.e0" id="DBMI.pac72.sp1.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac72.sp2" origId="sp2" text="Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects. If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibitors. Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved."/>
	<sentencespan id="DBMI.pac72.sp3" origId="sp3" text="[see Clinical Pharmacology (12.3)]\n\nCYP3A4 Inducers\nA published study showed that the co-administration of rifampin, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations. Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone. If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inducers.">
		<entity charOffset="1800-1809" id="DBMI.pac72.sp3.e0" origId="sp3.e0" text="rifampin " type="Active ingredient"/>
		<entity charOffset="1877-1887" id="DBMI.pac72.sp3.e1" origId="sp3.e1" text="oxycodone " type="Active ingredient"/>
		<pair e1="DBMI.pac72.sp3.e0" e2="DBMI.pac72.sp3.e1" id="DBMI.pac72.sp3.p0" interaction="true" interactionPhraseType="Qualitative" modality="Positive" object="oxycodone " precipitant="rifampin "/>
		<pair e1="DBMI.pac72.sp3.e1" e2="DBMI.pac72.sp3.e0" id="DBMI.pac72.sp3.p1" interaction="false" interactionPhraseType="" modality="" object="" precipitant=""/>
	</sentencespan>
	<sentencespan id="DBMI.pac72.sp4" origId="sp4" text="Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved. [see Clinical Pharmacology (12.3)]\n\nCYP2D6 Inhibitors\nOxycodone is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent."/>
	<sentencespan id="DBMI.pac72.sp5" origId="sp5" text="However, clinicians should be aware of this possible interaction. 7.5 Monoamine Oxidase Inhibitors (MAOIs)\n\nNo specific interaction between oxycodone and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate. 7.6 Anticholinergics\n\nAnticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus."/>
</document>
